CEUAX
Price
$62.60
Change
-$0.14 (-0.22%)
Updated
Sep 18 closing price
Net Assets
140.03B
TIOHX
Price
$17.80
Change
+$0.27 (+1.54%)
Updated
Sep 17 closing price
Net Assets
2.61B
Interact to see
Advertisement

CEUAX vs TIOHX

CEUAX vs TIOHX Comparison Chart in %
View a ticker or compare two or three
VS
CEUAX vs. TIOHX commentary
Sep 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CEUAX is a StrongBuy and TIOHX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CEUAX has more cash in the bank: 140B vs. TIOHX (2.61B). CEUAX pays higher dividends than TIOHX: CEUAX (2.52) vs TIOHX (1.85). CEUAX was incepted earlier than TIOHX: CEUAX (25 years) vs TIOHX (11 years). CEUAX (0.86) is less costly to investors than TIOHX (0.68). TIOHX is a more actively managed with annual turnover of: 58.00 vs. CEUAX (50.00). CEUAX has a lower initial minimum investment than TIOHX: CEUAX (250) vs TIOHX (100000). TIOHX annual gain was more profitable for investors over the last year : 4.42 vs. CEUAX (2.04). CEUAX return over 5 years is better than : -4.19 vs. TIOHX (-6.58).
CEUAXTIOHXCEUAX / TIOHX
Total Expense Ratio0.860.68126%
Annual Report Gross Expense Ratio0.860.68126%
Fund Existence25 years11 years-
Gain YTD5.4237.74870%
Front Load4%N/A-
Min. Initial Investment2501000000%
Min. Initial Investment IRAN/AN/A-
Net Assets140B2.61B5,364%
Annual Yield % from dividends2.521.85136%
Returns for 1 year2.044.4246%
Returns for 3 years27.2834.6779%
Returns for 5 years-4.19-6.5864%
Returns for 10 years51.8487.7659%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FACGX185.571.03
+0.56%
Fidelity Advisor Growth Opps C
HIBCX52.180.13
+0.25%
Hartford Capital Appreciation HLS IB
RYVFX11.69-0.06
-0.51%
Royce Small-Cap Value Service
HFCSX34.31-0.19
-0.55%
Hennessy Focus Investor
FBTDX170.40-3.12
-1.80%
Franklin Biotechnology Discovery C